Abnormal pontine activation in pathological laughing as shown by functional magnetic resonance imaging

To explore the aetiology of pathological laughing, a 65-year-old woman with pathological laughing was examined by 3-T functional magnetic resonance imaging (fMRI) before and after treatment with drugs. Here, we report that the patient consistently showed exaggerated pontine activation during the performance of three tasks before treatment, whereas abnormal pontine activation was no longer found after successful treatment with the selective serotonin reuptake inhibitor, paroxetine. Our findings in this first fMRI study of pathological laughing suggest that serotonergic replacement decreases the aberrant activity in a circuit that involves the pons

「生きられる空間」の複相性をめぐって : 文学テクストに見る出来事の表象と記憶の問題

2007-03-31departmental bulletin pape

The Trek and Other Stories

Much has been said over the last decade about the forcible eviction of the white farmers in Zimbabwe, less about the plight of the farm-workers, while the voice of the new settlers, and militia manipulated for a cause, has remained virtually unheard. This short but powerful anthology, The Trek and Other Stories, provides sensitive and illuminating, wry and comic perspectives on those people who occupied the land believing their future was golden, only for it to crumble in front of their faces

Figure S1 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer

Comprehensive copy number alterations analysis in CTC DNA. The heat map represents the copy number alterations of sixty genes in (A) 45 baseline and (B) 28 progression CTCs DNA samples at individual patient-level. Genomic copy gain is presented in red, and loss in blue color.</p

Supplementary Method from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer

Whole-exome sequencing and analysis of CTC-DNA.</p

Figure S3 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer

Comparing copy number alterations in CTCs DNA over time. A heat map shows the copy number alterations of sixty genes in 25 paired baseline and progression CTCs DNA, longitudinally at individual patient-level. Genomic copy gain is presented in red, loss in blue, and no change in white color.</p

Figure S6 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer

Visualization of reference vs. alternate alleles in sensitive vs. resistant CTCs DNA. All the COSMIC validated mutations uniquely detected in sensitive and resistant CTCs DNA was visualized in the IGV genome browser with sequence read depth coverage, shown as snapshot images.</p

File S4 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer

The table representing the copy number and mutation data together for all 11 baseline and paired progression CTCs DNA samples.</p

Table S1 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer

Top pathways enriched at baseline (N=45) and progression (N=28) during ingenuity pathway analysis (IPA, Qiagen). Selection criteria; top genes altered in >=40% of the cases.</p

File S1 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer

Commonly altered genes present in >=40% of baseline cases (N=45).</p